TAS-0612 is under clinical development by Taiho Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAS-0612’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAS-0612 is under development for the treatment of solid tumors including HER2 negative breast cancer and triple negative breast cancer. It is administered by oral route as tablets. It targets protein kinase B (AKT), 70 kDa ribosomal protein S6 kinase (p70S6K) and ribosomal protein S6 kinase alpha 3 (pp90RSK2).
Taiho Oncology overview
Taiho Oncology, a subsidiary of Taiho Pharmaceutical Co Ltd, is a provider of cancer treatments and solutions. The company manufactures and markets cancer anti-metabolites as well as targeted small molecule inhibitors. Its products portfolio includes oral drugs for the treatment of gastric cancer, colorectal cancer and a variety of solid tumors. Taiho Oncology’s pipeline products includes anti metabolic agents and selectively targeted agents. The company’s LONSURF is an anti cancer drug for the treatment of metastatic colorectal cancer. Taiho Oncology is headquartered in Princeton, New Jersey, the US.
For a complete picture of TAS-0612’s drug-specific PTSR and LoA scores, buy the report here.